drugset / Trial / NCT00181688
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer
Phase 2
Completed
35 enrolled
Massachusetts General Hospital
Brigham and Women's Hospital · collabDana-Farber Cancer Institute · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to determine the effects (good and bad) Iressa plus anastrozole has on patients with relapsed ovarian cancer.
Timeline
- Start
- 2003-10
- Primary completion
- 2006-03
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | — | Oral |
| Subject | Gefitinib | Small molecule | — | Oral |